Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to hemophilia: hemophilia B




Hemophilia is a genetic disorder—usually inherited—of the mechanism of blood clotting. Depending on the degree of the disorder present in an individual, excess bleeding may occur only after specific, predictable events (such as surgery, dental procedures, or injury), or occur spontaneously, with no known initiating event.


The normal mechanism for blood clotting is a complex series of events involving the interaction of the injured blood vessel, blood cells (called platelets), and over 20 different proteins which also circulate in the blood.
When a blood vessel is injured in a way that causes bleeding, platelets collect over the injured area, and form a temporary plug to prevent further bleeding. This temporary plug, however, is too disorganized to serve as a long-term solution, so a series of chemical events occur, resulting in the formation of a more reliable plug. The final plug involves tightly woven fibers of a material called fibrin. The production of fibrin requires the interaction of several chemicals, in particular a series of proteins called clotting factors. At least thirteen different clotting factors have been identified.
The clotting cascade, as it is usually called, is the series of events required to form the final fibrin clot. The cascade uses a technique called amplification to rapidly produce the proper sized fibrin clot from the small number of molecules initially activated by the injury.
In hemophilia, certain clotting factors are either decreased in quantity, absent, or improperly formed. Because the clotting cascade uses amplification to rapidly plug up a bleeding area, absence or inactivity of just one clotting factor can greatly increase bleeding time.
Hemophilia A is the most common type of bleeding disorder and involves decreased activity of factor VIII. There are three levels of factor VIII deficiency: severe, moderate, and mild. This classification is based on the percentage of normal factor VIII activity present:
  • Individuals with less than 1% of normal factor VIII activity level have severe hemophilia. Half of all people with hemophilia A fall into this category. Such individuals frequently experience spontaneous bleeding, most frequently into their joints, skin, and muscles. Surgery or trauma can result in life-threatening hemorrhage, and must be carefully managed.
  • Individuals with 1-5% of normal factor VIII activity level have moderate hemophilia, and are at risk for heavy bleeding after seemingly minor traumatic injury.
  • Individuals with 5-40% of normal factor VIII activity level have mild hemophilia, and must prepare carefully for any surgery or dental procedures.
Individuals with hemophilia B have symptoms very similar to those of hemophilia A, but the deficient factor is factor IX. This type of hemophilia is also known as Christmas disease.
Hemophilia C is very rare, and much more mild than hemophilia A or B; it involves factor XI.
Hemophilia A affects between one in 5,000 to one in 10,000 males in most populations.
One recent study estimated the prevalence of hemophilia was 13.4 cases per 100,000 U.S. males (10.5 hemophilia A and 2.9 hemophilia B). By race/ethnicity, the prevalence was 13.2 cases/100,000 among white, 11.0 among African-American, and 11.5 among Hispanic males.

Causes and symptoms

Hemophilia A and B are both caused by a genetic defect present on the X chromosome. (Hemophilia C is inherited in a different fashion.) About 70% of all people with hemophilia A or B inherited the disease. The other 30% develop from a spontaneous genetic mutation.
The following concepts are important to understanding the inheritance of these diseases. All humans have two chromosomes determining their gender: females have XX, males have XY. Because the trait is carried only on the X chromosome, it is called "sex-linked." The chromosome's flawed unit is referred to as the gene.
Both factors VIII and IX are produced by a genetic defect of the X chromosome, so hemophilia A and B are both sex-linked diseases. Because a female child always receives two X chromosomes, she nearly always will receive at least one normal X chromosome. Therefore, even if she receives one flawed X chromosome, she will still be capable of producing a sufficient quantity of factors VIII and IX to avoid the symptoms of hemophilia. Such a person who has one flawed chromosome, but does not actually suffer from the disease, is called a carrier. She carries the flaw that causes hemophilia and can pass it on to her offspring. If, however, she has a son who receives her flawed X chromosome, he will be unable to produce the right quantity of factors VIII or IX, and he will suffer some degree of hemophilia. (Males inherit one X and one Y chromosome, and therefore have only one X chromosome.)
In rare cases, a hemophiliac father and a carrier mother can pass on the right combination of parental chromosomes to result in a hemophiliac female child. This situation, however, is rare. The vast majority of people with either hemophilia A or B are male.
About 30% of all people with hemophilia A or B are the first member of their family to ever have the disease. These individuals have had the unfortunate occurrence of a spontaneous mutation; meaning that in their early development, some random genetic accident befell their X chromosome, resulting in the defect causing hemophilia A or B. Once such a spontaneous genetic mutation takes place, offspring of the affected person can inherit the newly created, flawed chromosome.
In the case of severe hemophilia, the first bleeding event usually occurs prior to eighteen months of age. In some babies, hemophilia is suspected immediately, when a routine circumcision (removal of the foreskin of the penis) results in unusually heavy bleeding. Toddlers are at particular risk, because they fall frequently, and may bleed into the soft tissue of their arms and legs. These small bleeds result in bruising and noticeable lumps, but don't usually need treatment. As a child becomes more active, bleeding may occur into the muscles; a much more painful and debilitating problem. These muscle bleeds result in pain and pressure on the nerves in the area of the bleed. Damage to nerves can cause numbness and decreased ability to use the injured limb.
Some of the most problematic and frequent bleeds occur into the joints, particularly into the knees and elbows. Repeated bleeding into joints can result in scarring within the joints and permanent deformities. Individuals may develop arthritis in joints that have suffered continued irritation from the presence of blood. Mouth injuries can result in compression of the airway, and, therefore, can be life-threatening. A blow to the head, which might be totally insignificant in a normal individual, can result in bleeding into the skull and brain. Because the skull has no room for expansion, the hemophiliac individual is at risk for brain damage due to blood taking up space and exerting pressure on the delicate brain tissue.
People with hemophilia are at very high risk of hemorrhage (severe, heavy, uncontrollable bleeding) from injuries such as motor vehicle accidents and also from surgery.
Some other rare clotting disorders such as Von Willebrand disease present similar symptoms but are not usually called hemophilia.


Various tests are available to measure, under very carefully controlled conditions, the length of time it takes to produce certain components of the final fibrin clot. Tests called assays can also determine the percentage of factors VIII and IX present compared to normal percentages. This information can help in demonstrating the type of hemophilia present, as well as the severity.
Individuals with a family history of hemophilia may benefit from genetic counseling before deciding to have a baby. Families with a positive history of hemophilia can also have tests done during a pregnancy to determine whether the fetus is a hemophiliac. The test called chorionic villous sampling examines proteins for the defects that lead to hemophilia. This test, which is associated with a 1% risk of miscarriage, can be performed at 10-14 weeks. The test called amniocentesis examines the DNA of fetal cells shed into the amniotic fluid for genetic mutations. Amniocentesis, which is associated with a one in 200 risk of miscarriage, is performed at 15-18 weeks gestation.


The most important thing that individuals with hemophilia can do to prevent complications of this disease is to avoid injury. Those individuals who require dental work or any surgery may need to be pre-treated with an infusion of factor VIII to avoid hemorrhage. Also, hemophiliacs should be vaccinated against hepatitis. Medications or drugs that promote bleeding, such as aspirin, should be avoided.
Various types of factors VIII and IX are available to replace a patient's missing factors. These are administered intravenously (directly into the patient's veins
Hemophilia A and B are both caused by a genetic defect present on the X chromosome. Approximately 70% of people with hemophilia A or B inherited the disease, while the remaining 30% have hemophilia due to a spontaneous genetic mutation.
Hemophilia A and B are both caused by a genetic defect present on the X chromosome. Approximately 70% of people with hemophilia A or B inherited the disease, while the remaining 30% have hemophilia due to a spontaneous genetic mutation.
(Illustration by Electronic Illustrators Group.)
by needle). These factor preparations may be obtained from a single donor, by pooling the donations of as many as thousands of donors, or by laboratory creation through highly advanced genetic techniques.
The frequency of treatment with factors depends on the severity of the individual patient's disease. Patients with relatively mild disease will only require treatment in the event of injury, or to prepare for scheduled surgical or dental procedures. Patients with more severe disease will require regular treatment to avoid spontaneous bleeding.
While appropriate treatment of hemophilia can both decrease suffering and be life-saving, complications associated with treatment can also be quite serious. About 20% of all patients with hemophilia A begin to produce chemicals in their bodies which rapidly destroy infused factor VIII. The presence of such a chemical may greatly hamper efforts to prevent or stop a major hemorrhage.
Individuals who receive factor prepared from pooled donor blood are at risk for serious infections that may be passed through blood. Hepatitis, a severe and potentially fatal viral liver infection, may be contracted from pooled factor preparations. Recently, a good deal of concern has been raised about the possibility of hemophiliacs contracting a fatal slow virus infection of the brain (Creutzfeldt-Jakob disease) from blood products. Unfortunately, pooled factor preparations in the early 1980s were contaminated with human immunodeficiency virus (HIV), the virus which causes AIDS. A large number of hemophiliacs were infected with HIV and some statistics show that HIV is still the leading cause of death among hemophiliacs. Currently, careful methods of donor testing, as well as methods of inactivating viruses present in donated blood, have greatly lowered this risk.
The most exciting new treatments currently being researched involve efforts to transfer new genes to hemophiliacs. These new genes would have the ability to produce the missing factors. As yet, these techniques are not being performed on humans, but there is great hope that eventually this type of gene therapy will be available.


Prognosis is very difficult to generalize. Because there are so many variations in the severity of hemophilia, and because much of what befalls a hemophiliac patient will depend on issues such as physical activity level and accidental injuries, statistics on prognosis are not generally available.

Key terms

Amplification — A process by which something is made larger. In clotting, only a very few chemicals are released by the initial injury; they result in a cascade of chemical reactions which produces increasingly larger quantities of different chemicals, resulting in an appropriately-sized, strong fibrin clot.
Factors — Coagulation factors are substances in the blood, such as proteins and minerals, that are necessary for clotting. Each clotting substance is designated with roman numerals I through XIII.
Fibrin — The final substance created through the clotting cascade, which provides a strong, reliable plug to prevent further bleeding from the initial injury.
Hemorrhage — Very severe, massive bleeding that is difficult to control. Hemorrhage can occur in hemophiliacs after what would be a relatively minor injury to a person with normal clotting factors.
Mutation — A permanent change in the genetic material that may alter a trait or characteristic of an individual, or manifest as disease, and can be transmitted to offspring.
Platelets — Small disc-shaped structures that circulate in the blood stream and participate in blood clotting.
Trauma — Injury.



Khoury, Muin J., Wylie Burke, and Elizabeth J. Thomson, editors. Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford University Press, 2000.
Resnick, Susan. Blood Saga: Hemophilia, AIDS, and the Survival of a Community. Berkeley: University of California Press, 1999.


Stephenson, J. "New Therapies Show Promise for Patients with Leukemia, Hemophilia, and Heart Disease." JAMA 285 (January 1, 2001): 153+.


National Hemophilia Foundation. 116 West 32nd St., 11th Floor, New York, NY 10001. (800) 42-HANDI. 〈http://www.info@hemophilia.org〉.
National Organization for Rare Disorders (NORD). PO Box 8923, New Fairfield, CT 06812-8923. (203) 746-6518 or (800) 999-6673. Fax: (203) 746-6481. http://www.rarediseases.org.


March of Dimes. www.modimes.org.
National Organization for Rare Disorders. 〈www.rarediseases.org〉.


a hereditary disorder characterized by a strong tendency to bleed. The most common types are carried as sex-linked genes with females carrying the trait and disease manifestations almost always in males. (Occasionally, women carrying the trait for hemophilia A or B have bleeding manifestations themselves, probably as a result of nonrandom inactivation of their X chromosomes and overexpression of the X chromosome coding for hemophilia; these women are referred to as symptomatic carriers.) All daughters of affected men will be carriers for the gene of hemophilia.

The two most common types are hemophilia A and hemophilia B. Over 80 per cent of patients have hemophilia A (classical hemophilia), which is characterized by a deficiency of coagulation factor VIII. Hemophilia B (called also Christmas disease) affects about 15 per cent of hemophiliacs and is characterized by a deficiency of coagulation factor IX. Other coagulation factor deficiencies are less common, with patients suffering either milder bleeding or thrombotic episodes.
Symptoms. Bleeding in hemophilic patients is variable, depending on the level of deficiency of the clotting factor. Approximately 60 per cent of persons with hemophilia A or B are severely affected and may have spontaneous bleeding without any recognized trauma. Soft tissue bleeding from the neck, lower face, and tongue may cause grave consequences if not treated. Hematuria and gastrointestinal bleeding are likely, and hemarthrosis (bleeding into joints) can lead to painful stiffening and permanent disability. The leading cause of death, however, is intracranial bleeding. Hemorrhagic complications can be avoided or minimized with early and adequate factor replacement therapy.

Hemophilia A is characterized by a factor VIII level of from 0 to 30 per cent of normal. The partial thromboplastin time (PTT) is usually prolonged. The platelet count, bleeding time, and prothrombin time (PT) are normal. In hemophilia B there is a low factor IX level and the prothrombin time is usually prolonged.
Treatment. The treatment of persons with hemophilia depends on the severity of their disease and the nature of a given bleeding episode. Several therapeutic materials are available for correction of the clotting defect in hemophilia A. Factor VIII is present in commercial lyophilized factor VIII concentrates, cryoprecipitate, fresh whole blood, and fresh frozen plasma. Purified factor VIII concentrate, however, is the treatment of choice. Successful treatment of those with mild hemophilia A can often be done with desmopressin (DDAVP). While factor IX is present in fresh frozen plasma, it is not concentrated in cryoprecipitate, so that the latter is not useful for treatment of hemophilia B. Factor IX is present in two commercially prepared concentrates, known as factor IX complex concentrates and coagulation factor IX concentrates.

All persons with hemophilia should be immunized with hepatitis B vaccine. Suspected bleeding into the central nervous system must be promptly treated; when this happens, consultation with or transfer to a Hemophilia Treatment Center is mandatory. Early treatment of hemarthroses is essential for maintenance of joint health; infusions administered within 4 to 6 hours of onset of symptoms are sufficient to stop bleeding and restore joint function. Medically supervised home infusion therapy has become an integral part of the comprehensive care of patients with bleeding disorders and has facilitated the treatment of bleeding episodes outside the hospital setting.
Patient Care. Advances in therapy have greatly improved the prognosis and management of hemophilia, but new issues have emerged, including the impact on immune status of purer factor concentrates, escalating financial considerations, and therapeutics for infections with hepatitis B, hepatitis C, and the human immunodeficiency virus. Multidisciplinary comprehensive care that incorporates patient and family educational strategies continues to be an essential element of care. Surgery and dental care require a team approach by individuals with specialized knowledge and expertise, in order to ensure favorable outcomes. A diagnosis of hemophilia presents many challenges, not the least of which are psychosocial issues.

Excellent sources of information for both professionals and nonprofessionals are the National Hemophilia Foundation, 110 Greene St., Suite 303, New York, NY 10012 (telephone 212-219-8180) and the Hemophilia and AIDS/HIV Network for the Dissemination of Information (“HANDI”) at the same address (telephone 800-42-HANDI).
hemophilia A classical hemophilia, a sex-linked condition due to deficiency of coagulation factor VIII; see hemophilia.
hemophilia B a form similar to hemophilia A but due to a deficiency of coagulation factor IX; called also Christmas disease. See hemophilia.
hemophilia C an inherited disorder caused by a lack of coagulation factor XI.. It has been observed mostly in persons of Ashkenazi Jewish ancestry and is characterized by recurring episodes of minor bleeding and mild bruising, severe prolonged bleeding after surgical procedures, and prolonged recalcification and partial thromboplastin times. Called also plasma thromboplastin antecedent deficiency, PTA deficiency, and Rosenthal syndrome.


An inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhages, spontaneous or traumatic, because of a defect in the blood-coagulating mechanism.
[hemo- + G. philos, fond]


/he·mo·phil·ia/ (he″mo-fil´e-ah) a hereditary hemorrhagic diathesis due to deficiency of a blood coagulation factor.
hemophilia A  classical h.; an X-linked recessive form due to deficiency of coagulation factor VIII.
hemophilia B  Christmas disease; an X-linked recessive form due to deficiency of coagulation factor IX.
hemophilia C  an autosomal disorder due to lack of coagulation factor XI; seen predominantly in persons of Jewish ancestry and characterized by minor bleeding, mild bruising, severe prolonged postsurgical bleeding, and abnormal clotting test times.
classical hemophilia  h. A.
vascular hemophilia  von Willebrand's disease.


(hē′mə-fĭl′ē-ə, -fēl′yə)
Any of several sex-linked genetic disorders, manifested almost exclusively in males, in which the blood fails to clot normally because of a deficiency or an abnormality of one of the clotting factors.


[hē′mōfē′lyə, hem′-]
Etymology: Gk, haima + philein, to love
a group of hereditary bleeding disorders characterized by a deficiency of one of the factors necessary for coagulation of the blood. The two most common forms of the disorder are hemophilia A and hemophilia B. Hemophilia A (classic hemophilia) is the result of a deficiency or absence of coagulation factor VIII. Hemophilia B (Christmas disease) results from a deficiency of factor IX. Hemophilia C (Rosenthal disease) is a factor XI deficiency. The clinical severity of the disorder varies with the extent of the deficiency. Anatomical bleeding-bleeding into joints, muscles, and soft tissue-is typical of hemophilia. Greater than usual loss of blood during dental procedures, epistaxis, hematoma, and hemarthrosis are common problems in patients with hemophilia. Also spelled haemophilia. See also von Willebrand disease, specific blood factors. hemophiliac, n., hemophilic, adj.
observations The primary presenting sign in hemophilia is excessive, poorly controlled bleeding. The rate of bleeding depends on the amount of factor activity and the severity of the injury that caused the bleeding. A factor activity level below 1% can cause spontaneous bleeding or severe bleeding from even minor trauma. When the factor activity level is more than 5%, bleeding is usually caused by trauma and is more easily controlled. The bleeding is anatomical involving subcutaneous and muscle tissue, or deep bleeding into joints and organ systems. Laboratory tests reveal a normal prothrombin time, a prolonged partial thromboplastin time, and a normal platelet function. Assays are used to determine the factor affected and the level of factor activity. A common cause of death is intracranial bleeds, which occur in about 10% of hemophiliacs and are fatal 30% of the time. Other complications of repeat bleeds include joint and musculoskeletal deformities, pericardial tamponade, airway compression, and uncontrolled hemorrhage.
interventions Replacement of deficient factors with recombinant factor products or plasma-derived factor concentrates is the primary treatment. This may be used as prophylaxis or to stop bleeding episodes. Desmopressin acetate is used to stimulate factor VIII in mild hemophilia A. Aminocaproic acid is given in cases of persistent bleeding unresponsive to treatment. Pain is controlled with acetaminophen or codeine. Aspirin and NSAID use and intramuscular injections should be avoided because they may precipitate bleeding. Extreme care must be exercised when these individuals need surgery or dental work.
enlarge picture
Inheritance patterns in hemophilia


Hematology Any of 3 inherited coagulopathies due to deficiency of coagulation factor VIII–hemophilia A, factor IX–hemophilia B, factor XI–Rosenthal's disease or hemophilia C. Cf Thalassemia.


An inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhages, spontaneous or traumatic, due to a defect in the blood coagulating mechanism.
Synonym(s): haemophilia.
[hemo- + G. philos, fond]

hemophilia (hēˈ·mō·fēˑ·lē·),

n genetically transmitted condition that impairs or prevents blood from clotting.
Enlarge picture


Inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhages, spontaneous or traumatic, because of a defect in the blood-coagulating mechanism.
Synonym(s): haemophilia.
[hemo- + G. philos, fond]

hemophilia (bleeder's disease) (hē´mōfil´ēə),

n a sex-linked genetic disease manifested in males and characterized by severe hemorrhage.
hemophilia A (classic hemophilia),
n a hemorrhagic diathesis resulting from a deficiency of antihemophilic globulin (AHG); inherited as a recessive sex-linked characteristic and characterized by recurrent bouts of bleeding from even trivial injury. The coagulation time is prolonged, but the bleeding time is normal.
hemophilia B (Christmas disease, hemophilia II, hemophilioid state C),
n a hemorrhagic diathesis resulting from a deficiency of plasma thromboplastin component (PTC); transmitted as a sex-linked recessive characteristic and characterized clinically by the same manifestations as classic hemophilia. There is a delay in the generation of thromboplastin. The platelet count, bleeding time, tourniquet test, and thrombin and prothrombin times are normal.
hemophilia C (plasma thromboplastin antecedent [PTA] deficiency, Rosenthal's syndrome),
n a hemophilia-like condition believed to result from a deficiency of plasma thromboplastin antecedent (PTA), transmitted as a simple autosomal dominant trait and characterized by a moderate bleeding tendency after extraction of teeth or after tonsillectomy. Prothrombin consumption and thromboplastin generation are abnormal. See also factor XI.
hemophilia, classic,
n See hemophilia A.
hemophilia, vascular,
n a hereditary hemorrhagic disorder affecting both sexes and associated with a deficiency of antihemophilic globulin and vascular abnormalities characteristic of pseudohemophilia (von Willebrand disease). The bleeding time is prolonged, and severity of bleeding varies considerably among persons with this condition.


a condition characterized by impaired coagulability of the blood, and a strong tendency to bleed. See also deficiency of the following clotting factors, afibrinogenemia and hypoprothrombinemia, and proconvertin, stuart factor, plasma thromboplastin antecedent, hageman factor and fibrin stabilizing factor.

hemophilia A
classical hemophilia, due to deficiency of clotting factor VIII-C; occurs in dogs, horses and cats and is transmitted by the female to the male as a sex-linked recessive abnormality.
hemophilia B
a form similar to classical hemophilia but due to a deficiency of clotting factor IX; called also christmas disease and factor IX deficiency. Occurs in dogs and cats.
hemophilia C
in dogs an autosomal dominant form due to deficiency of clotting factor XI (plasma thromboplastin antecedent). Called also factor XI deficiency. The disease also occurs in cattle but the clinical disease is minor and it is inherited as a recessive character.
double hemophilia
dogs with both hemophilia A and hemophilia B have been produced experimentally.
vascular hemophilia
deficiency of clotting factor VIII and factor VIII-related antigen occurs in many breeds of dogs, particularly Doberman Pinschers, and in rabbits and pigs. See also von willebrand's disease.
References in periodicals archive ?
The amount of clotting factors provided to children with hemophilia by the state is very small to let children live normal life, representative of the Compulsory Health Insurance Fund said.
Different organisations related to prevention and care of hemophilia all over the Sindh imparted education to hemophilia patients to increase their awareness of thid disease.
As many as one-third of patients with severe or moderately severe hemophilia A are at risk for developing inhibitors, which are antibodies produced by the body's immune system in response to factor replacement therapy.
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced.
There are thought to be up to 1,000 people with hemophilia and other bleeding disorders living in Lebanon, but only one third of them have been diagnosed.
People with severe hemophilia live in fear of cuts and bruises, which bleed profusely and require prompt injections of expensive medication.
This week, a scientific team reports using gene therapy to treat dogs with a canine version of hemophilia B, an inherited bleeding disease that afflicts one of every 30,000 persons.
OBI-1 has the potential to address existing unmet needs of hemophilia patients and is a strong strategic fit with Baxter's current hemophilia portfolio," said Bruce Ewenstein, M.
This donation has the potential to impact people living with hemophilia B in more than 40 countries worldwide," said Alain Weill, WFH president.
He and his colleagues at Vanderbilt University in Nashville and The Orthopedic Hospital in Los Angeles analyzed mutations in the Factor VIII genes of 30 patients with severe hemophilia A and 17 patients with milder forms of the disorder.
Inspiration Biopharmaceuticals (Inspiration) andIpsen (Euronext: IPN; ADR: IPSEY)today announced the sale of its lead hemophilia program, OBI-1 (recombinant porcine factor VIII), to Baxter International (Baxter), the global leader in hemophilia.
These wide-ranging data uncover the tremendous burden hemophilia has on both patients and caregivers and reinforces the importance of an individualized treatment approach for this chronic disease," said David Cooper, MD, Senior Director, Medical Affairs, Novo Nordisk.